BioMarin Pharmaceutical Inc.: Wedbush cuts target price to $89 from $94
BMRN•Wedbush cut its target price for BioMarin Pharmaceutical to $89 from $94.
Related News
US research roundup: Bright Minds Biosciences, Marvell Technology, Oracle
MRVL•
CPKC sets all-time monthly grain shipment record in October
CP•
Expeditors Q3 2026 diluted EPS jumps 62% to USD 2.65
EXPD•
BBVA Argentina redirects Class 50 bond proceeds to debt refinancing
BBAR•
Dine Brands rejects $39-a-share buyout offer from Arkhouse and Cobblers Cove
DIN•